Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.
AUTHORS
Chen
WH ,
Jackson
LA ,
Edwards
KM ,
Keitel
WA ,
Hill
H ,
Noah
DL ,
Creech
CB ,
Patel
SM ,
Mangal
B ,
Kotloff
KL ,
. Clinical and vaccine immunology : CVI. 2015 11 11; ().
- PMID: 26561390 [PubMed].
ABSTRACT
The adjuvant AS03 is stockpiled for future formulation with new and existing vaccines for control of pandemic influenza. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to one year after vaccination.
The adjuvant AS03 is stockpiled for future formulation with new and existing vaccines for control of pandemic influenza. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to one year after vaccination.
Tags: Alumni Publications 2015